p53 Is a Determinant of X-Linked Inhibitor of Apoptosis Protein/Akt-Mediated Chemoresistance in Human Ovarian Cancer Cells

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7081-7088

  Fraser, Michael ^a   Leung, Brendan M ^a   Yan, Xiaojuan ^a   Dan, Han C ^b   Cheng, Jin Q ^b   Tsang, Benjamin K ^a,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APOPTOSIS INHIBITOR; CISPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIFITHRIN ALPHA HYDROBROMIDE; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN P53; PROTEIN P53 INHIBITOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION; WILD TYPE; X CHROMOSOME LINKAGE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEIN P53; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 0242610903     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X., Jiang, C., Coppola, D., Nicosia, S. V., and Cheng, J. Q. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene, 19: 2324-2330, 2000.
2. Lasky, T., and Silbergeld, E. P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. Environ. Health Perspect., 104: 1324-1331, 1996.
3. Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C., X-linked IAP is a direct inhibitor of cell-death proteases. Nature (Lond.). 388: 300-304, 1997.
4. Li, J., Feng, Q., Kim, J. M., Schneiderman, D., Liston, P., Li, M., Vanderhyden, B., Faught, W., Fung, M. F., Senterman, M., Korneluk, R. G., and Tsang, B. K. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology, 142: 370-380, 2001.
5. Sasaki, H., Sheng, Y., Kotsuji, F., and Tsang, B. K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res., 60: 5659-5666, 2000.
6. Asselin, E., Mills, G. B., and Tsang, B. K., XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res., 61: 1862-1868, 2001.
7. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
8. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (Wash. DC), 278: 687-689, 1997.
9. Jiang, K., Coppola, D., Crespo, N. C., Nicosia, S. V., Hamilton, A. D., Sebti, S. M., and Cheng, J. Q. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol., 20: 139-148, 2000.
10. Tang, Y., Zhou, H., Chen, A., Pittman, R. N., and Field, J. The Akt proto-oncogene links Ras to Pak and cell survival signals. J. Biol. Chem., 275: 9106-9109, 2000.
11. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96: 857-868, 1999.
12. Suhara, T., Kim, H. S., Kirshenbaum, L. A., and Walsh, K. Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol. Cell. Biol., 22: 680-691, 2002.
13. Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke T. F., Hamilton, T. C., Tsichlis, P. N., and Testa, J. R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA, 89: 9267-9271, 1992.
14. Yuan, Z. Q., Feldman, R. I., Sussman, G. E., Coppola, D., Nicosia, S. V., and Cheng, J. Q. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASKI: implication of AKT2 in chemoresistance. J. Biol. Chem., 278: 23432-23440, 2003.
15. Krieg, T., Landsberger, M., Alexeyev, M. F., Felix, S. B., Cohen, M. V., and Downey, J. M. Activation of Akt is essential for acctylcholine to trigger generation of oxygen free radicals. Cardiovasc. Res., 58: 196-202, 2003.
16. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., and Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in vitro and iu vivo ovarian cancer models. Cancer Res., 62: 1087-1092, 2002.
17. Arango, D., Corner, G. A., Wadler, S., Catalano, P. J., and Augenlicht, L. H. c-mye/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res., 61: 4910-4915, 2001.
18. Komarov, P. G., Komarova, E. A., Kondralov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., and Gudkov, A. V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science (Wash. DC), 285: 1733-1737, 1999.
19. Zhang, M., Liu, W., Ding, D., and Salvi, R. Pifithfin-α suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience, 120: 191-205, 2003.
20. Kimet, L. M., Cook, L. S., and Magliocco, A. M. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer (Phila.), 97: 389-404, 2003.
21. Wen, S. F., Mahavni, V., Quijano, E., Shinoda, J., Grace, M., Musco-Hobkinson, M. L., Yang, T. Y., Chen, Y., Runnenbaum, I., Horowitz, J., Maneval, D., Hutchins, B., and Buller, R. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther., 10: 224-238. 2003.
22. Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T,. Tanaka. K., Masuyama, N., and Gotoh, Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem., 277: 21843-21850, 2002.
23. Qin, L. F., and Ng, I. O. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett., 175: 27-38, 2002.
24. Deveraux, Q. L., Leo, E., Stennicke, H. R., Welsh, K., Salvesen, G. S., and Reed. J. C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J., 18: 5242-5251, 1999.
25. Schneiderman, D., Kim, J-M., Senterman, M., and Tsang, B. K. Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells. Apoptosis, 4: 271-282, 1999.
26. Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M., and Ashwell, J. D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (Wash. DC), 288: 874-877, 2000.
27. Wang, Y., Chan, S., and Tsang, B. K. Involvement of inhibitory nuclear factor-κB (NFκB)-independent NFκB activation in the gonadotropic regulation of X-linked inhibitor of apoptosis expression during ovarian follicular development in vitro. Endocrinology, 143: 2732-2740, 2002.